JERUSALEM, Sept. 20, 2018
/PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the
Company") today announces that Company management will participate
at the following upcoming investment conferences.
Oppenheimer 2018 Fall Summit - Focused on Specialty Pharma
and Rare Disease
Date: September
26-27, 2018
Location: Langham Hotel, New York
City
Presenter: Jeffrey A. Meckler, Vice Chairman and Chief Executive
Officer of Intec Pharma
Format: One-on-One Investor Meetings
Ladenburg Thalmann 2018 Healthcare
Conference
Date: October 2,
2018
Company Presentation: 2:00 pm Eastern
time
Location: Sofitel, New York
City
Presenter: Walt A. Linscott, Chief Business Officer of Intec
Pharma
Format: Corporate presentation and One-on-One Investor Meetings
Mr. Linscott's presentation will be webcast live and will be
accessible through the Events section of Intec Pharma's website at
www.intecpharma.com, where it will also be archived for a period of
time.
About Intec Pharma Ltd.
Intec Pharma is a clinical-stage biopharmaceutical company
focused on developing drugs based on its proprietary Accordion Pill
platform technology. The Company's Accordion Pill is an oral drug
delivery system that is designed to improve the efficacy and safety
of existing drugs and drugs in development by utilizing an
efficient gastric retention and specific release mechanism. The
Company's product pipeline includes two product candidates in
clinical trial stages: Accordion Pill Carbidopa/Levodopa, or
AP-CD/LD, which is in late-stage Phase 3 development for the
treatment of Parkinson's disease symptoms in advanced Parkinson's
disease patients, and AP-cannabinoids, an Accordion Pill to deliver
either or both of the primary cannabinoids contained in Cannabis
sativa, cannabidiol (CBD) and tetrahydrocannabinol (THC) for
various indications including low back neuropathic pain and
fibromyalgia.
For more information, visit www.intecpharma.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward looking statements about our
expectations, beliefs and intentions. Forward-looking statements
can be identified by the use of forward-looking words such as
"believe", "expect", "intend", "plan", "may", "should", "could",
"might", "seek", "target", "will", "project", "forecast",
"continue" or "anticipate" or their negatives or variations of
these words or other comparable words or by the fact that these
statements do not relate strictly to historical matters. These
forward-looking statements are based on assumptions and assessments
made in light of management's experience and perception of
historical trends, current conditions, expected future developments
and other factors believed to be appropriate. Forward-looking
statements in this press release are made as of the date of this
press release, and we undertake no duty to update or revise any
such statements, whether as a result of new information, future
events or otherwise. Forward-looking statements are not guarantees
of future performance and are subject to risks and uncertainties,
many of which are outside of our control. Many factors could cause
our actual activities or results to differ materially from the
activities and results anticipated in forward-looking statements,
including, but not limited to, the following: our limited operating
history and history of operating losses, our ability to continue as
a going concern, our ability to obtain additional financing, our
ability to successfully operate our business or execute our
business plan, the timing and cost of our clinical trials, the
completion and receiving favorable results in our clinical trials,
our ability to obtain and maintain regulatory approval of our
product candidates, our ability to protect and maintain our
intellectual property and licensing arrangements, our ability to
develop, manufacture and commercialize our product candidates, the
risk of product liability claims, the availability of
reimbursement, and the influence of extensive and costly government
regulation. More detailed information about the risks and
uncertainties affecting us is contained under the heading "Risk
Factors" included in our most recent Annual Report on Form 20-F
filed with the SEC on March 9, 2018,
and in other filings that we have made and may make with the
Securities and Exchange Commission in the future.
Intec Pharma Investor Contact:
Anne Marie
Fields
VP-Corporate Communications & Investor Relations
+1-646-200-8808
amf@intec-us.com
View original
content:http://www.prnewswire.com/news-releases/intec-pharma-to-participate-at-upcoming-investment-conferences-300715964.html
SOURCE Intec Pharma Ltd.